Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
News|Articles|December 8, 2023
Infectious Disease News for This Week
Author(s)John Parkinson
This week's news looked at the medical and economic burden of AMR, why the implementation of new College of American Pathologists rules presents an opportunity for collaboration between microbiology labs and ID providers, which specific antibiotics showed the greatest associations with adverse drug reaction case reports related to C diff, and how infants with HIV could be spared from requiring lifetime ART if treated within hours of birth.
Advertisement
Advertisement
Related to this article
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
CDC lists 5 active multistate outbreaks tied to oysters, raw milk cheese, sprouts, and pet turtles, with recalls in effect for 4 of them.
Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.
Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.
MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point
4
Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases
5